Background: Mentoring in Palliative Medicine is critical to training, career satisfaction and professional development. Yet, there are no accounts of effective mentoring programs in Palliative Medicine. This gap is attributed to a failure to define mentoring practice and a lack of acknowledgment of mentoring's context-specific, goal-sensitive, mentee-, mentor-and organizational-dependent nature that has hindered effective review of mentoring programs.

No abstract

No abstract

TRANSLATIONAL RELEVANCEUnderstanding resistance to targeted therapy requires in depth analysis at multiple levels (single gene, chromosome, transcriptome). Our results illustrate the interplay between genetic alterations, cell lineage plasticity and the tumor microenvironment in shaping divergent TKI resistance and outcome trajectories in EGFR mutated NSCLC. Transcriptomic analysis revealed ubiquitous loss of adenocarcinoma lineage gene expression in T790M negative tumors. TP53 alterations, 3q chromosomal amplifications, whole genome doubling and non-aging mutational signatures were also enriched in T790M negative tumors. Genomic and transcriptomic profiling may facilitate the design of bespoke therapeutic approaches tailored to a tumor's adaptive potential.

IMPORTANCEThe recently published ADAURA study has posed a significant dilemma for clinicians in selecting patients for adjuvant osimertinib. Risk factors for recurrence in early-stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) also remain undefined. OBJECTIVE To determine clinicopathologic characteristics and recurrence patterns of resectedearly-stage EGFR-positive NSCLC, using wildtype EGFR as a comparator cohort, and identify features associated with recurrence. DESIGN, SETTING, AND PARTICIPANTS This is a cohort study including patients diagnosed with